94 related articles for article (PubMed ID: 9374331)
1. Comparison between technetium-99m-sestamibi and hydrogen-3-daunomycin myocardial cellular retention in vitro.
Cayre A; Moins N; Finat-Duclos F; Verrelle P; Maublant J
J Nucl Med; 1997 Nov; 38(11):1674-7. PubMed ID: 9374331
[TBL] [Abstract][Full Text] [Related]
2. Comparative 99mTc-sestamibi and 3H-daunomycin uptake in human carcinoma cells: relation to the MDR phenotype and effects of reversing agents.
Cayre A; Moins N; Finat-Duclos F; Maublant J; Verrelle P
J Nucl Med; 1999 Apr; 40(4):672-6. PubMed ID: 10210228
[TBL] [Abstract][Full Text] [Related]
3. Effects of MDR reversing agent combinations on the 3H-daunomycin accumulation in drug-sensitive and drug-resistant human cancer cells.
Moins N; Cayre A; Chevillard S; Maublant J; Verrelle P; Finat-Duclos F
Anticancer Res; 2000; 20(4):2617-23. PubMed ID: 10953334
[TBL] [Abstract][Full Text] [Related]
4. In vitro detection of the MDR phenotype in rat myocardium: use of PCR, [3H]daunomycin and MDR reversing agents.
Cayre A; Moins N; Finat-Duclos F; Maublant J; Albuisson E; Verrelle P
Anticancer Drugs; 1996 Nov; 7(8):833-7. PubMed ID: 8991186
[TBL] [Abstract][Full Text] [Related]
5. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression.
Cordobes MD; Starzec A; Delmon-Moingeon L; Blanchot C; Kouyoumdjian JC; Prévost G; Caglar M; Moretti JL
J Nucl Med; 1996 Feb; 37(2):286-9. PubMed ID: 8667063
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein versus MRP1 on transport kinetics of cationic lipophilic substrates: a comparative study using [99mTc]sestamibi and [99mTc]tetrofosmin.
Gomes CM; Abrunhosa AJ; Pauwels EK; Botelho MF
Cancer Biother Radiopharm; 2009 Apr; 24(2):215-27. PubMed ID: 19409044
[TBL] [Abstract][Full Text] [Related]
7. [Effect of S9788, cyclosporin A and verapamil on intracellular accumulation of doxorubicin, daunorubicin and daunorubicinol in primary rat hepatocyte culture].
Le Bot MA; Kernaleguen D; Simon I; Berlion M; Riché C
Ann Biol Clin (Paris); 1996; 54(1):21-4. PubMed ID: 8731791
[TBL] [Abstract][Full Text] [Related]
8. Myocardial kinetics of 99m technetium-Q agents: studies in isolated cardiac myocyte, isolated perfused rat heart, and canine regional myocardial ischemia models.
McGoron AJ; Biniakiewicz D; Millard RW; Kumar A; Kennedy SC; Roszell NJ; Gabel M; Huth C; Walsh RA; Gerson MC
Invest Radiol; 1999 Nov; 34(11):704-17. PubMed ID: 10548383
[TBL] [Abstract][Full Text] [Related]
9. Myocardial technetium-99m-tetrofosmin and technetium-99m-sestamibi kinetics in normal subjects and patients with coronary artery disease.
Münch G; Neverve J; Matsunari I; Schröter G; Schwaiger M
J Nucl Med; 1997 Mar; 38(3):428-32. PubMed ID: 9074532
[TBL] [Abstract][Full Text] [Related]
10. Effects of a new triazinoaminopiperidine derivative on adriamycin accumulation and retention in cells displaying P-glycoprotein-mediated multidrug resistance.
Léonce S; Pierré A; Anstett M; Pérez V; Genton A; Bizzari JP; Atassi G
Biochem Pharmacol; 1992 Nov; 44(9):1707-15. PubMed ID: 1360210
[TBL] [Abstract][Full Text] [Related]
11. Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi.
Rao VV; Chiu ML; Kronauge JF; Piwnica-Worms D
J Nucl Med; 1994 Mar; 35(3):510-5. PubMed ID: 7906729
[TBL] [Abstract][Full Text] [Related]
12. Comparison of (99m)Tc-sestamibi and doxorubicin to monitor inhibition of P-glycoprotein function.
Muzzammil T; Moore MJ; Hedley D; Ballinger JR
Br J Cancer; 2001 Feb; 84(3):367-73. PubMed ID: 11161402
[TBL] [Abstract][Full Text] [Related]
13. Effects of verapamil and S9788 on MDR-1 mRNA expression studied by in situ hybridization.
Joly P; Lallemand A; Oum'Hamed Z; Trentesaux C; Idoine O; Desplaces A
Anticancer Res; 1996; 16(6B):3609-14. PubMed ID: 9042229
[TBL] [Abstract][Full Text] [Related]
14. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.
Piwnica-Worms D; Chiu ML; Budding M; Kronauge JF; Kramer RA; Croop JM
Cancer Res; 1993 Mar; 53(5):977-84. PubMed ID: 8094997
[TBL] [Abstract][Full Text] [Related]
15. [In vitro characterization of S9788, a new modulator of multidrug resistance].
Pérez V; Pierré A; Léonce S; Anstett M; Prost JF; Atassi G
Bull Cancer; 1993 Apr; 80(4):310-25. PubMed ID: 8173185
[TBL] [Abstract][Full Text] [Related]
16. Detection of P-glycoprotein activity in endotoxemic rats by 99mTc-sestamibi imaging.
Wang JH; Scollard DA; Teng S; Reilly RM; Piquette-Miller M
J Nucl Med; 2005 Sep; 46(9):1537-45. PubMed ID: 16157538
[TBL] [Abstract][Full Text] [Related]
17. 99mTc-sestamibi kinetics predict myocardial viability in a perfused rat heart model.
Liu Z; Okada DR; Johnson G; Hocherman SD; Beju D; Okada RD
Eur J Nucl Med Mol Imaging; 2008 Mar; 35(3):570-8. PubMed ID: 17952434
[TBL] [Abstract][Full Text] [Related]
18. Effects of miltefosine on membrane permeability and accumulation of [99mTc]-hexakis-2-methoxyisobutyl isonitrile, 2-[18F]fluoro-2-deoxy-D-glucose, daunorubucin and rhodamine123 in multidrug-resistant and sensitive cells.
Márián T; Balkay L; Trón L; Krasznai ZT; Szabó-Péli J; Krasznai Z
Eur J Pharm Sci; 2005 Apr; 24(5):495-501. PubMed ID: 15784339
[TBL] [Abstract][Full Text] [Related]
19. Technetium-99m-furifosmin as an agent for functional imaging of multidrug resistance in tumors.
Ballinger JR; Muzzammil T; Moore MJ
J Nucl Med; 1997 Dec; 38(12):1915-9. PubMed ID: 9430469
[TBL] [Abstract][Full Text] [Related]
20. Reversal of multidrug resistance: lessons from clinical oncology.
Bates SF; Chen C; Robey R; Kang M; Figg WD; Fojo T
Novartis Found Symp; 2002; 243():83-96; discussion 96-102, 180-5. PubMed ID: 11990784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
